Динамика распространенности и чувствительности БЛРС-продуцирующих и чувствительности БЛРС-продуцирующих штаммов энтеробактерий к различным и чувствительности БЛРС-продуцирующих штаммов энтеробактерий к различным антимикробным препаратам в ОРИТ России | КМАХ

Динамика распространенности и чувствительности БЛРС-продуцирующих и чувствительности БЛРС-продуцирующих штаммов энтеробактерий к различным и чувствительности БЛРС-продуцирующих штаммов энтеробактерий к различным антимикробным препаратам в ОРИТ России

Клиническая Микробиология и Антимикробная Химиотерапия. 2005; 7(3):287-300

​ Эйдельштейн М.В., Страчунский Л.С., исследовательская группа РОСНЕТ
β-лактамазы расширенного спектра энтеробактерии нозокомиальные инфекции
Раздел
Антибиотикорезистентность
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2005; 7(3):287-300

Аннотация

Изучена распространенность продукции β-лактамаз расширенного спектра (БЛРС) среди нозокомиальных штаммов энтеробактерий, выделенных в ОРИТ различных регионов России в 1997–1998 гг. и 2003 г. Выявлено стремительное нарастание частоты встречаемости БЛРС, в основном за счет распространениея β-лактамаз CTX-M-типа. Результаты оценки чувствительности штаммов-продуцентов БЛРС к различным препаратам in vitro свидетельствуют о значительном снижении активности небеталактамных препаратов (амикацина и ципрофлоксацина) за указанный период. Препаратами выбора для терапии нозокомиальных инфекций, вызванных продуцентами БЛРС, остаются карбапенемы и цефоперазон/сульбактам.

  • 1. Finegold, S. M. In vitro efficacy of beta-lactam/ beta-lactamase inhibitor combinations against bacteria involved in mixed infections. Int.J.Antimicrob.Agents 1999;12 Suppl 1:S9-14.
  • 2. Kimura, K., Y. Arakawa, S. Ohsuka, H. Ito, K. Suzuki, H. Kurokawa, N. Kato, and M. Ohta. Molecular aspects of high-level resistance to sulbactam-cefoperazone in Klebsiella oxytoca clinical isolates. Antimicrob.Agents Chemother. 1996; 40:1988-1994.
  • 3. McLaughlin, J. C., A. L. Barry, P. C. Fuchs, E. H. Gerlach, D. J. Hardy, and M. A. Pfaller. In-vitro activity of five beta-lactam/beta-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosa. J.Antimicrob.Chemother. 1994; 33:223-230.
  • 4. Nomura, S., H. Hanaki, and A. Nagayama. Tazo bactam-piperacillin compared with sulbac tam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections. J.Chemother. 1997; 9:89-94.
  • 5. Rice, L. B., L. L. Carias, L. Etter, and D. M. Shlaes. Resistan ce to cefoperazone-sulbactam in Klebsiella pneumoniae: evidence for enhanced resistance resulting from the coexistence of two different resistance mechanisms. Antimicrob.Agents Chemother. 1993; 37:1061-1064.
  • 6. Burgess, D. S. and R. G. Hall. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae. Diagn.Microbiol.Infect. Dis. 2004; 49:41-46.
  • 7. Kang, C.I., H. Pai, S.H. Kim, H.B. Kim, E.C. Kim, M.D. Oh, and K.W. Choe. Cefepime and the ino cu lum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase. J.Antimicrob.Chemother. 2004; 54:1130-1133.
  • 8. Thomson, K. S. and E. S. Moland. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob.Agents Chemother. 2001; 45:3548-3554.
  • 9. Queenan, A. M., B. Foleno, C. Gownley, E. Wira, and K. Bush. Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J.Clin.Microbiol. 2004; 42:269-275.
  • 10. Edelstein, M., Edelstein, I., Semchenkova, D., and Strat chounski, L. The effect of large inoculaon in vitro activities of penicillin-inhibitor combinations and cefoperazone-sulbactam against ESBL-producing Escherichia coli and Klebsiella pneumoniae strains. (14th European Congress of Clinical Microbiology and Infectious Diseases), P1723. 2004. Prague. 2004.
  • 11. Procop, G. W., M. J. Tuohy, D. A. Wilson, D. Williams, E. Hadziyannis, and G. S. Hall. Cross-class resistance to non-beta-lactam antimicrobials in extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Am.J.Clin.Pathol. 2003; 120:265-267.
  • 12. Spanu, T., F. Luzzaro, M. Perilli, G. Amicosante, A. Toniolo, and G. Fadda. Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs. Antimicrob.Agents Chemother. 2002; 46:196-202.
  • 13. Winokur, P. L., M. V. Eidelstain, O. Stetsiouk, L. Stratchounski, J. Blahova, G. K. Reshedko, M. A. et al. Russian Klebsiella pneumoniae isolates that express extended-spectrum beta-lactamases. Clin.Microbiol. Infect. 2000; 6:103-108.
  • 14. Paterson, D. L., L. Mulazimoglu, J. M. Casellas, W. C. Ko, H. Goossens, A. Von Gottberg, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin. Infect.Dis. 2000; 30:473-478.
  • 15. Yu, W. L., R. N. Jones, R. J. Hollis, S. A. Messer, D. J. Biedenbach, L. M. Deshpande, and M. A. Pfaller. Molecular epidemiology of extended-spectrum beta-lac tamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan. J.Clin.Microbiol. 2002; 40:4666-4669.
  • 16. Graffunder, E. M., K. E. Preston, A. M. Evans, and R. A. Venezia. Risk factors associated with extended-spectrum {beta}-lactamase-producing organisms at a tertiary care hospital. J.Antimicrob.Chemother. 2005.
  • 17. Sirot, D., C. De Champs, C. Chanal, R. Labia, A. Darfeuille-Michaud, R. Perroux, and J. Sirot. Translocation of antibiotic resistance determinants including an extended-spectrum beta-lactamase between conjugative plasmids of Klebsiella pneumoniae and Escherichia coli. Antimicrob.Agents Chemother. 1991; 35:1576-1581.
  • 18. Araque, M. and I. Rivera. Simultaneous presence of blaTEM and blaSHV genes on a large conjugative plasmid carried by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Am. J. Med. Sci. 2004; 327:118-122.
  • 19. Mammeri, H., L. M. Van De, L. Poirel, L. Martinez-Martinez, and P. Nordmann. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob.Agents Chemother. 2005; 49:71-76.
  • 20. Wang, M., D. F. Sahm, G. A. Jacoby, and D. C. Hooper. Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob.Agents Chemother. 2004; 48:1295-1299.
  • 21. Jones, R. N. and M. A. Pfaller. Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe. Clin. Microbiol.Infect. 2003; 9:708-712.
  • 22. Bouchillon, S. K., B. M. Johnson, D. J. Hoban, J. L. Johnson, M. J. Dowzicky, D. H. Wu, et al. Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002. Int.J.Antimicrob.Agents 2004; 24:119-124.
  • 23. Nijssen, S., A. Florijn, M. J. Bonten, F. J. Schmitz, J. Verhoef, and A. C. Fluit. Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates. Int. J.Antimicrob.Agents 2004; 24:585-591.
  • 24. Edelstein, M., M. Pimkin, I. Palagin, I. Edelstein, and L. Stratchounski. Prevalence and molecular epidemiology of CTX-M extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospitals. Antimicrob.Agents Chemother. 2003; 47:3724-3732.
  • 25. Методические указания МУК 4.2.1890-04. 2004. Определение чувствительности микроорганизмов к антибактериальным препаратам.
  • 26. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: 14th informational supplement. NCCLS document M100-S14. 2004. National Committee for Clinical Laboratory Standards, Wayne, PA.
  • 27. Mabilat, C. and S. Goussard. 1993. PCR detection and identification of genes for extended-spectrum b-lactamases, p. 553-562. In: D. H. Persing, T. F. Smith, F. C. Tenover, and T. J. White (eds.), Diagnostic molecular microbiology. Principles and Applications. American Society for Microbiology, Washington, DC.
  • 28. Edelstein, M., M. Pimkin, T. Dmitrachenko, V. Semenov, N. Kozlova, D. Gladin, et al.. Multiple outbreaks of nosocomial salmonellosis in Russia and Belarus caused by a single clone of Salmonella enterica serovar Typhimurium producing an extended-spectrum beta-lactamase. Antimicrob.Agents Chemother. 2004; 48:2808-2815.
  • 29. Ekimov, A., Edelstein, M., and Belousov, E. A single-tube PCR with MGB Eclipse probes for detection of SHV-type extended-spectrum beta-lactamases (ESBLs). (14th European Congress of Clinical Microbiology and Infectious Diseases), 2004; P944. Prague.
  • 30. Edelstein, M., Ekimov, A., and Stratchounski, L. Prevalence of mutations conferring extended-spectrum activity on SHV beta-lactamases produced by nosocomial isolates of Enterobacteriaceae from Russian nationwide sur vey. (44th Interscience Conference on Antimicrobial Agents and Chemotherapy), 2004; C2-13
  • 31. Washington, DC. 31. Livermore, D. M. beta-Lactamases in laboratory and clinical resistance. Clin.Microbiol.Rev. 1995; 8:557-584.
  • 32. Paterson, D. L. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin. Microbiol.Infect. 2000; 6:460-463.
  • 33. Paterson, D. L., W. C. Ko, A. Von Gottberg, J. M. Casellas, L. Mulazimoglu, K. P. Klugman, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J.Clin.Microbiol. 2001; 39:2206-2212.
  • 34. Paterson, D. L., W. C. Ko, A. Von Gottberg, S. Mohapatra, J. M. Casellas, H. Goossens, et al. 2004. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin. Infect.Dis. 39:31-37.
  • 35. Szabo, D., A. Mathe, Z. Filetoth, P. Anderlik, L. Rokusz, and F. Rozgonyi. In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain. Antimicrob.Agents Chemother. 2001; 45:1287-1291.
  • 36. Paterson, D. L., W. C. Ko, A. Von Gottberg, S. Mohapatra, J. M. Casellas, H. Goossens, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann.Intern.Med. 2004; 140:26-32.
  • 37. Ambrose, P. G., S. M. Bhavnani, and R. N. Jones. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program. Antimicrob.Agents Chemother. 2003; 47:1643-1646.
  • 38. Maglio, D., C. Ong, M. A. Banevicius, Q. Geng, C. H. Nightingale, and D. P. Nicolau. Determination of the in vivo pharmacodynamic profile of cefepime against exten ded-spectrum-beta-lactamase-producing Escherichia coli at various inocula. Antimicrob.Agents Chemother. 2004; 48:1941-1947.
  • 39. Ромашов О. М., Яковлев С.В., Сидоренко С.В., и Бе ре зин А.Г. Эффективность цефепима при лечении нозокомиальных инфекций, вызванных энтеробактериями–продуцентами бета-лактамаз расширенного спектра. Инфекции и антимикробная терапия 2003; 5.
  • 40. Yakovlev, S., Romashov, O., Sidorenko, S. V., and Eryomina, L. Impact of extended-spectrum beta-lactamases produced by Gram-negative bacteria on efficacy of cephalosporins and quinolones. (15th European Congress of Clinical Microbiology and Infectious Diseases), 2005; P437. Copenhagen.
  • 41. Yu, W. L., M. A. Pfaller, P. L. Winokur, and R. N. Jones. Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae. Taiwan. Emerg.Infect.Dis. 2002; 8:522-524.
  • 42. Bonnet, R., J. L. Sampaio, R. Labia, C. De Champs, D. Sirot, C. Chanal, and J. Sirot. A novel CTX-M beta-lactamase (CTX-M-8) in cefotaxime-resistant Enterobacteriaceae isolated in Brazil. Antimicrob.Agents Chemother. 2000; 44:1936-1942.
  • 43. Bonnet, R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother. 2004; 48:1-14.
  • 44. Perilli M., D. Ettorre, B. Segatore, B. Caporale, F. De Santis, G. Pochetti, et al. Overexpression system and biochemical profile of CTX-M-3 extended-spectrum beta-lactamase expressed in Escherichia coli. FEMS Microbiol.Lett. 2004; 241:229-232.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились